<DOC>
	<DOCNO>NCT02643212</DOCNO>
	<brief_summary>The main objective study determine patient liver cirrhosis , anticoagulation free survival improve hypertension decompensation portal / transplantation without serious side effect . For conduct double-blind multicenter clinical trial patient randomize receive Rivaroxaban placebo . It include 160 patient liver cirrhosis insufficiency mild moderate hepatic . It also analyze develop secondary endpoint portal vein thrombosis . The confirmation hypothesis would lead radical change treatment patient cirrhosis include treatment Rivaroxaban drove .</brief_summary>
	<brief_title>Multicenter Prospective Randomized Trial Effect Rivaroxaban Survival Development Complications Portal Hypertension Patients With Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Aged 18 75 year sexes . Clinical / laboratory criterion , ultrasound / liver biopsy compatible diagnosis viral cirrhosis ( If hepatitis B virus : hepatitis B virusDNA must negative ; hepatitis C virus : sustain virologic response least 6 month prior enrollment ) ; alcohol ( last 6 month : men le 60 g daily intake woman le 40 g ) ; nonalcoholic steatohepatitis cryptogenic . Presence clinically significant portal hypertension define clinical criterion ( presence esophageal varix ascites ) , elastography ( liver FibroscanÂ® ? 21 kPa ) hemodynamic ( Hepatic venous pressure gradient &gt; 10 mmHg ) Mild moderate hepatic impairment define ChildPugh 710 point . Written inform consent participate study Any previous current thrombosis splenoportal axis ( must rule USDoppler earlier one month randomization ; doubt : compute tomography angiography magnetic resonance angiography require ) . Background hepatic encephalopathy grade II high Ascites require prior practice paracentesis last year d. Indication use anticoagulant / antiplatelet therapy reason . Hypersensitivity active ingredient excipients Active bleeding , clinically significant , risk major bleeding . Pregnancy lactation . Hepatocellular carcinoma malignant neoplasia time inclusion . Any comorbidity involve therapeutic limitation and/or life expectancy &lt; 12 month . Existence risk bleed esophageal varix prior variceal bleed . They may include full treatment ( stable beta blocker dosage eradication trough varix ligation ) . Pregnancy lactation . Severe thrombocytopenia &lt; 40,000 platelet / dl . Kidney failure ( creatinine clearance &lt; 15ml / min ) . Transjugular intrahepatic portosystemic shunt portosystemic shunt carrier . ChildPugh score great 10 . In hepatitis C virus liver cirrhosis patient : carry least six month sustain virologic response . In hepatitis B virus liver cirrhosis patient : hepatitis B virus DNA negative . Active alcoholism ( 60 g / day men 40 woman ) Use potent inhibitor cytochrome cytochrome P450 3A4 ( ketoconazole , protease inhibitor antiretroviral treatment human immunodeficiency virus patient ) cytochrome inductor ( rifampicin . Phenytoin ... ) . Participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>